Key Insights

Highlights

Success Rate

75% trial completion

Published Results

25 trials with published results (42%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

18.6%

11 terminated out of 59 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

10%

6 trials in Phase 3/4

Results Transparency

76%

25 of 33 completed with results

Key Signals

25 with results75% success11 terminated

Data Visualizations

Phase Distribution

56Total
Not Applicable (24)
Early P 1 (2)
P 1 (7)
P 2 (17)
P 3 (6)

Trial Status

Completed33
Terminated11
Active Not Recruiting9
Recruiting3
Withdrawn2
Unknown1

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 33 completed trials

Clinical Trials (59)

Showing 20 of 20 trials
NCT02488967Phase 3Active Not Recruiting

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

NCT02957968Phase 2Active Not Recruiting

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

NCT02445391Phase 3Active Not Recruiting

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

NCT01525966Phase 2Active Not Recruiting

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

NCT03414970Phase 3Active Not Recruiting

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

NCT02927912Phase 2Active Not Recruiting

Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction

NCT00066690Phase 3Completed

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT03345420Phase 2Completed

Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer

NCT02760030Phase 2Completed

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

NCT01750073Phase 2Active Not Recruiting

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

NCT04553770Phase 2Recruiting

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

NCT03284346Not ApplicableTerminated

Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors

NCT05512364Phase 3Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

NCT02400060Not ApplicableCompleted

Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer

NCT01730833Phase 2Active Not Recruiting

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

NCT03188393Phase 2Completed

Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery

NCT03198286Not ApplicableCompleted

Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors

NCT06926543Phase 3Recruiting

Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy

NCT01897441Not ApplicableTerminated

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

NCT02780401Phase 1Completed

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

Scroll to load more

Research Network

Activity Timeline